Study suggests antipsychotic drugs during pregnancy linked to increased risk of gestational diabetes

A study that examined maternal use of antipsychotic drugs during pregnancy suggests that these medications may be linked to an increased risk of gestational diabetes, according to a report in the July issue of Archives of General Psychiatry.

Severe , such as schizophrenia and , are usually treated with continuous , "however, the evidence concerning use of antipsychotics during pregnancy is generally lacking or weak," the authors write in the study background.

Robert Bodén. M.D., Ph.D., of the Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, and Uppsala University, Uppsala, Sweden, and colleagues used Swedish national health registers for a population-based study that also examined the effects of antipsychotic drugs during pregnancy on fetal growth.

Women who gave birth in Sweden from July 2005 through December 2009, were grouped by filled prescriptions for: (1) the antipsychotics olanzapine and/or clozapine (n=169); (2) other antipsychotics (n=338); or (3) no antipsychotics (n=357,696).

"Gestational diabetes was more than twice as common in mothers who used antipsychotics (seven mothers [4.1 percent] for group 1 and 15 [4.4 percent] for group 2) than in the total population of pregnant women (5,970 [1.7 percent])," according to the study results. The risk increase with olanzapine and/or clozapine was of similar magnitude but not statistical significance, the results indicate.

Women using antipsychotics also had an increased risk of giving birth to a small for gestational age (SGA) infant but, after adjusting for maternal factors, the risk was no longer statistically significant, according to the results.

"In conclusion, maternal use of antipsychotics during pregnancy, regardless of the drug group, is associated with an increased risk of gestational diabetes. The increased risk of giving birth to an SGA infant observed among women treated with antipsychotics during pregnancy is probably an effect of confounding factors, such as smoking," the authors comment.

The results also indicate there were no increased risks of being large for gestational age (LGA) for birth weight or birth length after exposure to olanzapine and/or clozapine, but the risk increased for head circumference.

"Pregnant women treated with should be closely monitored for and deviating fetal growth," the researchers conclude.

More information: Arch Gen Psychiatry. 2012;69[7]:715-721.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Fat chats: The good, the bad and the ugly comments

1 hour ago

Cyberbullying and hurtful 'fat jokes' are disturbingly prevalent in the social media environment, especially on Twitter, says Wen-ying Sylvia Chou of the National Institutes of Health in the US. Chou is lead ...

Omega-3 fatty acids may prevent some forms of depression

3 hours ago

Patients with increased inflammation, including those receiving cytokines for medical treatment, have a greatly increased risk of depression. For example, a 6-month treatment course of interferon-alpha therapy ...

Ethical behavior can be contagious, study says

4 hours ago

A new study from Penn State Smeal College of Business faculty members Steven Huddart and Hong Qu examines the power of social influence on managers' ethical behavior. The Department of Accounting researchers find that managers ...

Predicting the future course of psychotic illness

5 hours ago

University of Adelaide psychiatry researchers have developed a model that could help to predict a patient's likelihood of a good outcome from treatment – from their very first psychotic episode.

User comments